Nucleus RadioPharma, a Rochester, MN-based integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, raised $56M in Series A funding.
The round was led by Eclipse and GE HealthCare with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and University of Missouri.
The company intends to use the funds to establish multiple new manufacturing facilities around the country, including Rochester, Minnesota, near Mayo Clinic, and build novel technology for the development, manufacturing, and distribution of radiopharmaceuticals.
Led by CEO Charles S. Conroy, Nucleus RadioPharma is a CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. The company provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platform focuses on radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Nucleus offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle.